South Korea · Delayed Price · Currency is KRW HLB bioStep Statistics
Total Valuation
HLB bioStep has a market cap or net worth of KRW 100.60 billion. The enterprise value is 92.69 billion.
| Market Cap | 100.60B |
| Enterprise Value | 92.69B |
Important Dates
The last earnings date was Friday, November 14, 2025.
| Earnings Date | Nov 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
HLB bioStep has 84.47 million shares outstanding. The number of shares has increased by 0.82% in one year.
| Current Share Class | 84.47M |
| Shares Outstanding | 84.47M |
| Shares Change (YoY) | +0.82% |
| Shares Change (QoQ) | +60.40% |
| Owned by Insiders (%) | 1.00% |
| Owned by Institutions (%) | 0.50% |
| Float | 69.36M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.36 |
| PB Ratio | 1.00 |
| P/TBV Ratio | 1.10 |
| P/FCF Ratio | 90.38 |
| P/OCF Ratio | 32.60 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -4.89 |
| EV / Sales | 1.25 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 83.27 |
Financial Position
The company has a current ratio of 1.26, with a Debt / Equity ratio of 0.30.
| Current Ratio | 1.26 |
| Quick Ratio | 1.07 |
| Debt / Equity | 0.30 |
| Debt / EBITDA | n/a |
| Debt / FCF | 27.64 |
| Interest Coverage | -4.21 |
Financial Efficiency
Return on equity (ROE) is -18.60% and return on invested capital (ROIC) is -8.32%.
| Return on Equity (ROE) | -18.60% |
| Return on Assets (ROA) | -3.33% |
| Return on Invested Capital (ROIC) | -8.32% |
| Return on Capital Employed (ROCE) | -8.03% |
| Weighted Average Cost of Capital (WACC) | 4.22% |
| Revenue Per Employee | 503.74M |
| Profits Per Employee | -128.99M |
| Employee Count | 147 |
| Asset Turnover | 0.46 |
| Inventory Turnover | 12.09 |
Taxes
In the past 12 months, HLB bioStep has paid 2.73 billion in taxes.
| Income Tax | 2.73B |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -29.48% in the last 52 weeks. The beta is -0.06, so HLB bioStep's price volatility has been lower than the market average.
| Beta (5Y) | -0.06 |
| 52-Week Price Change | -29.48% |
| 50-Day Moving Average | 1,305.86 |
| 200-Day Moving Average | 1,390.60 |
| Relative Strength Index (RSI) | 41.87 |
| Average Volume (20 Days) | 275,802 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, HLB bioStep had revenue of KRW 74.05 billion and -18.96 billion in losses. Loss per share was -224.00.
| Revenue | 74.05B |
| Gross Profit | 55.91B |
| Operating Income | -8.64B |
| Pretax Income | -17.53B |
| Net Income | -18.96B |
| EBITDA | -3.91B |
| EBIT | -8.64B |
| Loss Per Share | -224.00 |
Balance Sheet
The company has 43.34 billion in cash and 30.76 billion in debt, with a net cash position of 12.58 billion or 148.90 per share.
| Cash & Cash Equivalents | 43.34B |
| Total Debt | 30.76B |
| Net Cash | 12.58B |
| Net Cash Per Share | 148.90 |
| Equity (Book Value) | 100.94B |
| Book Value Per Share | 816.09 |
| Working Capital | 12.63B |
Cash Flow
In the last 12 months, operating cash flow was 3.09 billion and capital expenditures -1.97 billion, giving a free cash flow of 1.11 billion.
| Operating Cash Flow | 3.09B |
| Capital Expenditures | -1.97B |
| Depreciation & Amortization | 4.73B |
| Net Borrowing | -2.75B |
| Free Cash Flow | 1.11B |
| FCF Per Share | 13.18 |
Margins
Gross margin is 75.50%, with operating and profit margins of -11.67% and -25.61%.
| Gross Margin | 75.50% |
| Operating Margin | -11.67% |
| Pretax Margin | -23.67% |
| Profit Margin | -25.61% |
| EBITDA Margin | -5.28% |
| EBIT Margin | -11.67% |
| FCF Margin | 1.50% |
Dividends & Yields
HLB bioStep does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.82% |
| Shareholder Yield | -0.82% |
| Earnings Yield | -18.85% |
| FCF Yield | 1.11% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 31, 2022. It was a forward split with a ratio of 9.
| Last Split Date | May 31, 2022 |
| Split Type | Forward |
| Split Ratio | 9 |
Scores
HLB bioStep has an Altman Z-Score of 1.97 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.97 |
| Piotroski F-Score | 4 |